Hearing loss is the highest single modifiable risk factor for dementia in the Lancet Commission framework, with an estimated population-attributable fraction of approximately 7%. The mechanism is multimodal: sensory deprivation increases cognitive load on a brain trying to process degraded auditory input; social withdrawal accelerates the isolation that is itself a dementia risk factor; the auditory cortex receives less input and may undergo accelerated atrophy. The clinical opportunity is substantial — and substantially unrealized. Approximately one-third of adults over 65 have hearing loss that would benefit from treatment; fewer than one in five of these patients actually wear hearing aids consistently.
The ACHIEVE trial, published in 2023, provided the strongest evidence to date that hearing aids specifically protect cognitive function. In a randomized trial of older adults with hearing loss, three years of hearing aid use reduced cognitive decline by approximately 48% in the higher-risk subgroup (older adults with additional dementia risk factors). The effect in the lower-risk subgroup was smaller and not statistically significant — suggesting that hearing aid benefit is most pronounced in patients already at elevated risk, who are also the patients for whom the intervention matters most. The trial moved hearing aid prescription from symptom relief into evidence-based dementia prevention.
The barriers to hearing aid adoption are real but addressable. Cost has historically been the dominant barrier in the United States, though the FDA's 2022 approval of over-the-counter hearing aids has changed this substantially. Stigma and identity — many patients see hearing aids as markers of aging that they are not ready to accept — produces resistance even when access is available. Fit, comfort, and adjustment to amplified sound require patience and adjustment periods that some patients abandon prematurely. The clinical work includes the prescription, the partnership through adjustment, and the follow-through that ensures the device is actually worn.
Screening for hearing loss should be active, not passive. Patients often do not recognize their own hearing loss until it is substantial. Spouses, family members, and clinicians often recognize the pattern earlier — turning up the television, asking for repetition, withdrawing from group conversations, mishearing. Formal audiometry is widely available and inexpensive. The longevity-psychiatry workup includes baseline audiometry for every patient in the acceleration window, with follow-up testing every several years and prompt intervention when treatable loss is identified. Mild hearing loss in patients with cognitive complaints deserves treatment even when the loss seems minor.
The intervention landscape is broader than traditional hearing aids. Cochlear implants for severe sensorineural hearing loss have evidence for cognitive benefit beyond what hearing aids can provide. Bone-anchored hearing devices for specific anatomical situations. Assistive listening devices and FM systems in specific settings. Hearing rehabilitation programs that address the cognitive and behavioral components of hearing loss adaptation. The clinical move is to know when each option applies and to partner with audiology and otolaryngology when the case is complex. For every patient with treatable hearing loss who is not currently receiving treatment, intervention is among the highest-leverage longevity-psychiatry moves available.